David Garate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Garate has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Thang
John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA
11 shared publications - John S. Barbieri
Department of Dermatology Brigham and Women's Hospital Boston Massachusetts USA
7 shared publications - Michael George Wilkerson
John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA
7 shared publications - George Golovko
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, USA
6 shared publications - Jenny Lai
Department of Dermatology, Brigham and Women’s Hospital, Boston, USA
4 shared publications - Alice Tang
Icahn School of Medicine at Mount Sinai
2 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 378
Bidirectional association between hidradenitis suppurativa and keloidal scarring: a population-based cohort study
- 24 August 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 378
Bidirectional association between hidradenitis suppurativa and keloidal scarring: a population-based cohort study
- 15 July 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (11) , 2427-2430
Population‐Based Trends and Disease‐Specific Survival in Microcystic Adnexal Carcinoma: A Surveillance, Epidemiology, and End Results ( SEER ) Program‐Based Analysis
- 15 July 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (11) , 2427-2430
Population‐Based Trends and Disease‐Specific Survival in Microcystic Adnexal Carcinoma: A Surveillance, Epidemiology, and End Results ( SEER ) Program‐Based Analysis
- 8 July 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (12) , 2638-2642
Association Between Omalizumab and Alopecia Areata Risk: A Retrospective Cohort Study
- 8 July 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (12) , 2638-2642
Association Between Omalizumab and Alopecia Areata Risk: A Retrospective Cohort Study
- 19 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1722-1724
Bidirectional Association Between Periorificial Dermatitis and Type 2 Inflammatory Conditions: A Retrospective Cohort Study
- 19 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1722-1724
Bidirectional Association Between Periorificial Dermatitis and Type 2 Inflammatory Conditions: A Retrospective Cohort Study
- 8 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Vitiligo and alopecia areata are not associated with an increased risk of venous thromboembolism: a large population-based cohort study
- 8 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Vitiligo and alopecia areata are not associated with an increased risk of venous thromboembolism: a large population-based cohort study
- 6 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Isotretinoin is not associated with an increased risk of diabetes: a retrospective cohort study
- 6 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Isotretinoin is not associated with an increased risk of diabetes: a retrospective cohort study
- 31 May 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (4) , 626-627
Granuloma annulare and the risk of autoimmune conditions: a multicentre retrospective cohort analysis
Prior studies and case reports have postulated potential associations between granuloma annulare (GA) and various autoimmune conditions, but these relationships remain unclear. Using the TriNetX Research Network, we found that GA was significantly associated with an increased risk of systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis and type 1 diabetes mellitus, along with point estimates suggesting an increased risk of systemic sclerosis and uveitis. Overall, our study uses epidemiological data to provide valuable evidence supporting an increased risk of autoimmune disorders in people with GA.
- 31 May 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (4) , 626-627
Granuloma annulare and the risk of autoimmune conditions: a multicentre retrospective cohort analysis
Prior studies and case reports have postulated potential associations between granuloma annulare (GA) and various autoimmune conditions, but these relationships remain unclear. Using the TriNetX Research Network, we found that GA was significantly associated with an increased risk of systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis and type 1 diabetes mellitus, along with point estimates suggesting an increased risk of systemic sclerosis and uveitis. Overall, our study uses epidemiological data to provide valuable evidence supporting an increased risk of autoimmune disorders in people with GA.
- 26 March 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (6) , 921-923
Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study
Dear Editor, Tetracycline-class antibiotics (e.g. doxycycline, minocycline and sarecycline) are the most commonly used systemic treatments for acne.1,2 While there have been concerns about tetracycline exposure and the risk of idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, there is uncertainty about this risk and whether it differs across different tetracycline-class antibiotics.1–5 To investigate whether tetracycline-class antibiotic exposure is associated with IIH development in people with acne, we conducted a population-based cohort study on the TriNetX US Collaborative Network (61 healthcare organizations). We identified patients with acne aged 14–40 years using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes (L70.0, L70.1, L70.5, L70.8, L70.9). Acne management was stratified into five treatment cohorts: (i) tetracycline-class antibiotic (RxNorm: 3640, 6980, 2059018); (ii) doxycycline (RxNorm: 3640); (iii) minocycline (RxNorm: 6980); (iv) sarecycline (RxNorm: 2059018); (iv) no systemic medications – patients with an encounter for acne and no exposure to isotretinoin (RxNorm: 6064), spironolactone (RxNorm: 9997), somatotropin (RxNorm: 61148), lithium (RxNorm: 6448) or a tetracycline-class antibiotic.1–5 To avoid the overlapping influence of different treatment regimens and treatment switching, we excluded patients who had any pre-existing or subsequent crossover exposure to the tetracyclines outside of their designated treatment cohort and other systemic treatments thought to be associated with IIH. The index date was defined as the first prescription for tetracycline (cohorts 1–4) or the first diagnosis of acne (cohort 5). Cohort comparisons were independently propensity score matched 1 : 1 using a greedy nearest-neighbour matching algorithm adjusted for index date, demographics (sex, race, ethnicity) and potential confounding comorbidities by ICD-10-CM designations: iron deficiency, haemolytic or idiopathic aplastic anaemia and aplastic anaemia, unspecified; type 2 diabetes mellitus; hypoparathyroidism; other disorders of adrenal gland; overweight and obesity; hypervitaminosis A; sleep apnoea; essential (primary) hypertension; systemic lupus erythematosus; acute kidney disease and chronic kidney disease; polycystic ovarian syndrome; primary thrombophilia; other thrombophilia.2,4,6 One-year Cox proportional hazards models with 95% confidence intervals (CIs) were assessed to evaluate the risk of IIH, with validated ICD-10-CM code G93.2.5 We also conducted a sensitivity analysis in which we additionally included the code H47.11 (papilledema associated with increased intracranial pressure). To reduce misclassification bias for our outcome of interest, we excluded patients with any ICD-10-CM diagnosis of malignant neoplasm of brain; meningitis; intracranial and intraspinal phlebitis and thrombophlebitis; hydrocephalus; cerebral infarction due to cerebral venous thrombosis, nonpyogenic; nonpyogenic thrombosis of intracranial venous system; cerebral venous thrombosis in pregnancy; Arnold Chiari syndrome.2,4
- 26 March 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (6) , 921-923
Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study
Dear Editor, Tetracycline-class antibiotics (e.g. doxycycline, minocycline and sarecycline) are the most commonly used systemic treatments for acne.1,2 While there have been concerns about tetracycline exposure and the risk of idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, there is uncertainty about this risk and whether it differs across different tetracycline-class antibiotics.1–5 To investigate whether tetracycline-class antibiotic exposure is associated with IIH development in people with acne, we conducted a population-based cohort study on the TriNetX US Collaborative Network (61 healthcare organizations). We identified patients with acne aged 14–40 years using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes (L70.0, L70.1, L70.5, L70.8, L70.9). Acne management was stratified into five treatment cohorts: (i) tetracycline-class antibiotic (RxNorm: 3640, 6980, 2059018); (ii) doxycycline (RxNorm: 3640); (iii) minocycline (RxNorm: 6980); (iv) sarecycline (RxNorm: 2059018); (iv) no systemic medications – patients with an encounter for acne and no exposure to isotretinoin (RxNorm: 6064), spironolactone (RxNorm: 9997), somatotropin (RxNorm: 61148), lithium (RxNorm: 6448) or a tetracycline-class antibiotic.1–5 To avoid the overlapping influence of different treatment regimens and treatment switching, we excluded patients who had any pre-existing or subsequent crossover exposure to the tetracyclines outside of their designated treatment cohort and other systemic treatments thought to be associated with IIH. The index date was defined as the first prescription for tetracycline (cohorts 1–4) or the first diagnosis of acne (cohort 5). Cohort comparisons were independently propensity score matched 1 : 1 using a greedy nearest-neighbour matching algorithm adjusted for index date, demographics (sex, race, ethnicity) and potential confounding comorbidities by ICD-10-CM designations: iron deficiency, haemolytic or idiopathic aplastic anaemia and aplastic anaemia, unspecified; type 2 diabetes mellitus; hypoparathyroidism; other disorders of adrenal gland; overweight and obesity; hypervitaminosis A; sleep apnoea; essential (primary) hypertension; systemic lupus erythematosus; acute kidney disease and chronic kidney disease; polycystic ovarian syndrome; primary thrombophilia; other thrombophilia.2,4,6 One-year Cox proportional hazards models with 95% confidence intervals (CIs) were assessed to evaluate the risk of IIH, with validated ICD-10-CM code G93.2.5 We also conducted a sensitivity analysis in which we additionally included the code H47.11 (papilledema associated with increased intracranial pressure). To reduce misclassification bias for our outcome of interest, we excluded patients with any ICD-10-CM diagnosis of malignant neoplasm of brain; meningitis; intracranial and intraspinal phlebitis and thrombophlebitis; hydrocephalus; cerebral infarction due to cerebral venous thrombosis, nonpyogenic; nonpyogenic thrombosis of intracranial venous system; cerebral venous thrombosis in pregnancy; Arnold Chiari syndrome.2,4